Similar articles

• [An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 1. Head and neck tumors].

  Niibe H, Takahashi I, Mitsuhashi N, Miyaishi K, Itoh J, Maehara Y, Nakajima N, Suto H, Sakaino K, Matsuura S, et al. Niibe H, et al. Nihon Gan Chiryo Gakkai Shi. 1985 Jun 20;20(5):984-93. Nihon Gan Chiryo Gakkai Shi. 1985. PMID: 2997351 Clinical Trial. Japanese. No abstract available.
• [Radioprotective effect of YM-08310 in radiotherapy of cervical cancer].

  Takahashi M, Abe M, Kawamura T, Iio A, Hamamoto K, Inohara T. Takahashi M, et al. Nihon Igaku Hoshasen Gakkai Zasshi. 1982 May 25;42(5):435-42. Nihon Igaku Hoshasen Gakkai Zasshi. 1982. PMID: 6294593 Japanese. No abstract available.
• [Clinical use of radioprotector amifostine (YM-08310)].

  Takahashi I, Mitsuhashi N, Itoh J, Okazaki A, Ikeda H, Suto H, Yamakawa M, Nozaki M, Miyaishi K, Niibe H. Takahashi I, et al. Nihon Igaku Hoshasen Gakkai Zasshi. 1984 Nov 25;44(11):1396-404. Nihon Igaku Hoshasen Gakkai Zasshi. 1984. PMID: 6099539 Japanese. No abstract available.
• The role of amifostine in the treatment of carcinoma of the uterine cervix: an update of RTOG-0116 and review of future directions.

  De Los Santos JF, Small W. De Los Santos JF, et al. Semin Oncol. 2004 Dec;31(6 Suppl 18):37-41. doi: 10.1053/j.seminoncol.2004.12.010. Semin Oncol. 2004. PMID: 15726521 Review.
• Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.

  Bourhis J, Rosine D. Bourhis J, et al. Semin Oncol. 2002 Dec;29(6 Suppl 19):61-2. doi: 10.1053/sonc.2002.37349. Semin Oncol. 2002. PMID: 12577247 Review.